The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy
Journal of Nuclear Medicine · 2023-08 · 64 (8) · 1252-1258
DOI: 10.2967/jnumed.122.265346 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.06.2023. Verfasst von Amir Karimzadeh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; amir.karimzadeh@uke.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; amir.karimzadeh@uke.de.
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, School of Medicine, Technical University of Munich, Munich, Germany; and.
- Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
- Institute of AI and Informatics in Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Zitieren
APA
Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., Haller, B., D'Alessandria, C., Weber, W. A., Eiber, M., & Rauscher, I. (2023). The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy. Journal of Nuclear Medicine, 64(8), 1252-1258. https://doi.org/10.2967/jnumed.122.265346
Vancouver
Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, et al. The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy. Journal of Nuclear Medicine. 2023;64(8):1252-1258. doi:10.2967/jnumed.122.265346
BibTeX
@article{Karimzadeh2023,
author = {Karimzadeh, Amir and Heck, Matthias and Tauber, Robert and Solaris, Esteban and Nekolla, Stephan and Knorr, Karina and Haller, Bernhard and D'Alessandria, Calogero and Weber, Wolfgang A and Eiber, Matthias and Rauscher, Isabel},
title = {The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {8},
pages = {1252--1258},
doi = {10.2967/jnumed.122.265346}
}
EUVIMED